Mr. Jinqiu (Edward) Tang has served as Anpac Bio’s Corporate Controller since October 2019 before becoming Chief Financial Officer. His experience includes:
Served as a global internal auditor at Natuzzi S.p.A.
Worked at Beijing Dongshen CPA and Shanghai De’an CPA providing external audit, finance, and tax advisory services across different industries and sectors.
Certified Public Accountant in Australia.
Received bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University in Australia, and his bachelor’s degree in law from Southwest University of Science and Technology in China.
Our world class leaders started with a question, “What if we could detect cancer before tumors start?”
Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.